Advanced BioMedical Technologies Inc. Begins Phase II Animal Test on PA Miniscrews and Plates

GUANGZHOU, CHINA and MIDDLETOWN, NY--(Marketwire - 11/16/09) - Advanced BioMedical Technologies Inc. (OTC.BB:ABMT - News) announced that the Company's subsidiary, Shenzhen Changhua Biomedical Engineering Co., Ltd. ("ABT-CHANGHUA"), has signed a cooperative agreement with The First Affiliated Hospital of Guangdong Pharmaceutical University ("GDPU Hospital") in Guangzhou. Under this cooperative agreement, both parties will join efforts in conducting research and animal tests on Cranio-Maxillofacial Fracture Treatment and Craniofacial Reconstruction utilizing ABT-CHANGHUA's novel patented PA (Polyamide) bio-absorbable material. ABT-CHANGHUA will produce sample PA bio-absorbable miniscrews and plates for research and animal test; GDPU Hospital will conduct research and animal testing, and a Phase II clinical trial for this new indication. The program will provide safety and efficacy data and provide further validation for the application of PA bio-degradable miniscrews and plates in Cranio-Maxillofacial Fracture Treatment, Craniofacial Restoration and Cosmetic Surgery.The Company intends to apply to the SFDA (State FDA of China) for Phase III clinical testing upon successful completion of its Phase II program. Under the agreement, both parties will contribute funding for the project but ABT-CHANGHUA has first right to file patent applications."The Company's bio-degradable, bio-absorbable materials are currently being applied to orthopaedic trauma treatment, and the Company has been seeking opportunities and cooperative ...
Click here to read the whole Article (external link)

Advanced BioMedical Technologies Inc. Completes Human Clinical Tests of PA Absorbable Orthopedic Implant Screw Required by the China State Food and Drug Administration (SFDA)

SHENZHEN, CHINA and MIDDLETOWN, NY--(Marketwire - 10/21/09) - Advanced BioMedical Technologies Inc. (OTC.BB:ABMT - News) announced that it has completed all 60 human clinical test cases of its PA Absorbable Orthopaedic Implant Screw according to the regulations set out by the China State Food and Drug Administration (SFDA). The actual number of test cases that have been taken in is 63. The Company is compiling trial reports and has entered the last stage of its clinical trial. The Company will apply for the SFDA final approval of this product as soon as the Comparison Data are prepared. "The successful taking in of 63 clinical test cases that were conducted at SFDA appointed hospitals is a milestone in our company's history. It symbolizes the approval of our technology by hospitals and doctors, and the acknowledgement and acceptance of our product by patients. We will commence production and marketing of our product as soon as we receive SFDA approval," said Ms Hui Wang, CEO of Advanced BioMedical Technologies Inc.A Post Clinical Test Summary Conference for Advanced BioMedical Technologies Inc.'s PA Orthopaedic Implant Screw and Wire was held in Teng Chun City, Yunnan Province, China during September 9 to 12. Twenty-five medical specialists and doctors from eight SFDA appointed GCP (Good Clinical Practice) hospitals attended this meeting. Speakers from each hospital presented their clinical test summary reports to the audience. Advanced BioMedical Technologies Inc. also had in depth discussion with the attendees on the foll...
Click here to read the whole Article (external link)

GEOSTAR MINERAL CORP Financials

Copyright © 2009 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service - Copyright/IP Policy - Send Feedback Quotes delayed, except where indicated otherwise.Delay times are 15 mins for NASDAQ, 20 mins for NYSE and Amex. See also delay times for other exchanges.Fundamental company data provided by Capital IQ. Quotes and other information supplied by independent providers identified on the Yahoo! Finance partner page. Quotes are updated automatically, but will be turned off after 25 minutes of inactivity. Quotes are delayed at least 15 minutes. Real-...
Click here to read the whole Article (external link)

GEOSTAR MINERAL CORP Files SEC form 10-Q, Quarterly Report

ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS This section of the report includes a number of forward-looking statements that reflect our current views with respect to future events and financial performance. Forward-looking statements are often identified by words like: believe, expect, estimate, anticipate, intend, project and similar expressions, or words which, by their nature, refer to future events. You should not place undue certainty on these forward-looking statements, which apply only as of the date of this annual report. These forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from historical results or our predictions. Overview The following discussion is an overview of the important factors that management focuses on in evaluating our businesses, financial condition and operating performance and should be read in conjunction with the financial statements included in this Quarterly Report on Form 10-Q. This discussion contains forward-looking statements that involve risks and uncertainties. Actual results could differ materially from those anticipated in these forward looking statements as a result of any number of factors, including those set forth in this Quarterly Report as well as under the section entitled "Risk Factors" and elsewhere in the Company's most recent Annual Report on Form 10-K filed on February 13, 2009. The Company is subject to a number of risks similar to other companies in the medical device industry. These risks include but are not limited to rapid technological change, uncertainty of market acceptance of our products, uncertainty of regulatory approval, competition from substitute products and larger companies, the need to obtain additional financing, compliance with government regulation, protection of proprietary technology, product liability, and the dependence on key individuals. ...
Click here to read the whole Article (external link)

GEOSTAR MINERAL CORP Files SEC form 10-Q/A, Quarterly Report

ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS This section of the report includes a number of forward-looking statements that reflect our current views with respect to future events and financial performance. Forward-looking statements are often identified by words like: believe, expect, estimate, anticipate, intend, project and similar expressions, or words which, by their nature, refer to future events. You should not place undue certainty on these forward-looking statements, which apply only as of the date of this annual report. These forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from historical results or our predictions. Overview The following discussion is an overview of the important factors that management focuses on in evaluating our businesses, financial condition and operating performance and should be read in conjunction with the financial statements included in this Quarterly Report on Form 10-Q. This discussion contains forward-looking statements that involve risks and uncertainties. Actual results could differ materially from those anticipated in these forward looking statements as a result of any number of factors, including those set forth in this Quarterly Report as well as under the section entitled "Risk Factors" and elsewhere in the Company's most recent Annual Report on Form 10-K filed on February 13, 2009. The Company is subject to a number of risks similar to other companies in the medical device industry. These risks include but are not limited to rapid technological change, uncertainty of market acceptance of our products, uncertainty of regulatory approval, competition from substitute products and larger companies, the need to obtain additional financing, compliance with government regulation, protection of proprietary technology, product liability, and the dependence on key individuals. ...
Click here to read the whole Article (external link)

GEOSTAR MINERAL CORP Files SEC form 10-Q, Quarterly Report

ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS This section of the report includes a number of forward-looking statements that reflect our current views with respect to future events and financial performance. Forward-looking statements are often identified by words like: believe, expect, estimate, anticipate, intend, project and similar expressions, or words which, by their nature, refer to future events. You should not place undue certainty on these forward-looking statements, which apply only as of the date of this annual report. These forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from historical results or our predictions. Overview The following discussion is an overview of the important factors that management focuses on in evaluating our businesses, financial condition and operating performance and should be read in conjunction with the financial statements included in this Quarterly Report on Form 10-Q. This discussion contains forward-looking statements that involve risks and uncertainties. Actual results could differ materially from those anticipated in these forward looking statements as a result of any number of factors, including those set forth in this Quarterly Report as well as under the section entitled "Risk Factors" and elsewhere in the Company's most recent Annual Report on Form 10-K filed on February 13, 2009. The Company is subject to a number of risks similar to other companies in the medical device industry. These risks include but are not limited to rapid technological change, uncertainty of market acceptance of our products, uncertainty of regulatory approval, competition from substitute products and larger companies, the need to obtain additional financing, compliance with government regulation, protection of proprietary technology, product liability, and the dependence on key individuals. ...
Click here to read the whole Article (external link)

GEOSTAR MINERAL CORP Files SEC form 10-Q, Quarterly Report

ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS This section of the report includes a number of forward-looking statements that reflect our current views with respect to future events and financial performance. Forward-looking statements are often identified by words like: believe, expect, estimate, anticipate, intend, project and similar expressions, or words which, by their nature, refer to future events. You should not place undue certainty on these forward-looking statements, which apply only as of the date of this annual report. These forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from historical results or our predictions. Overview The following discussion is an overview of the important factors that management focuses on in evaluating our businesses, financial condition and operating performance and should be read in conjunction with the financial statements included in this Quarterly Report on Form 10-Q. This discussion contains forward-looking statements that involve risks and uncertainties. Actual results could differ materially from those anticipated in these forward looking statements as a result of any number of factors, including those set forth in this Quarterly Report as well as under the section entitled "Risk Factors" and elsewhere in the Company's most recent Annual Report on Form 10-K filed on February 13, 2009. The Company is subject to a number of risks similar to other companies in the medical device industry. These risks include but are not limited to rapid technological change, uncertainty of market acceptance of our products, uncertainty of regulatory approval, competition from substitute products and larger companies, the need to obtain additional financing, compliance with government regulation, protection of proprietary technology, product liability, and the dependence on key individuals. ...
Click here to read the whole Article (external link)

GEOSTAR MINERAL CORP Files SEC form 10-K, Annual Report

ITEM 7. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS This section of the report includes a number of forward-looking statements that reflect our current views with respect to future events and financial performance. Forward-looking statements are often identified by words like: believe, expect, estimate, anticipate, intend, project and similar expressions, or words which, by their nature, refer to future events. You should not place undue certainty on these forward-looking statements, which apply only as of the date of this annual report. These forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from historical results or our predictions. Overview The following discussion is an overview of the important factors that management focuses on in evaluating our businesses, financial condition and operating performance and should be read in conjunction with the financial statements included in this Annual Report on Form 10-K. This discussion contains forward-looking statements that involve risks and uncertainties. Actual results could differ materially from those anticipated in these forward looking statements as a result of any number of factors, including those set forth under the section entitled "Risk Factors" and elsewhere in this Annual Report on Form 10-K. Factors that may cause actual results, our performance or achievements, or industry results to differ materially from those contemplated by such forward-looking statements include without limitation: 1. The company's lack of funds in new R&D, especially in clinical testing. 2. The company's lack of funds in new equipment and the utilization of the production process after SFDA approval. 3. The Company may need to seek funding through such vehicles as convertible notes and warrants, private placements, and/or convertible debentures. 4. The company ...
Click here to read the whole Article (external link)